<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, Oct. 17, 2018 (HealthDay News) — A seven-day dose of metronidazole is associated with a reduced likelihood of being Trichomonas vaginalis<\/i>-positive at test-of-cure compared with single-dose treatment, according to a study published online Oct. 5 in The Lancet Infectious Diseases<\/i>.<\/p>\n
Patricia Kissinger, Ph.D., from Tulane University in New Orleans, and colleagues conducted an open-label, randomized controlled trial involving HIV-uninfected, non-pregnant women positive for T. vaginalis<\/i> infection. Participants were randomly assigned to receive either a single dose of 2 g metronidazole (311 women) or 500 mg metronidazole twice daily for seven days (312 women).<\/p>\n
Planned enrollment in the study was 1,664 women, but due to funding limitations, the study was stopped early. The researchers found that compared with women in the single-dose group, those in the seven-day-dose group were less likely to be T. vaginalis<\/i> positive at test of cure four weeks after completion of treatment (11 versus 19 percent; relative risk, 0.55). There was no significant effect for bacterial vaginosis status on relative risk. Self-reported adherence was 96 and 99 percent in the seven-day-dose and single-dose groups, respectively. Similar side effects were seen in each group, with the most common side effects being nausea, headache, and vomiting.<\/p>\n
“We can no longer do something because it’s what we’ve always done. I hope that this study will help to change the recommendations so that women can get the proper treatment for this common curable sexually transmitted disease,” Kissinger said in a statement.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n Editorial (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n